PRESS RELEASES

Date Title and Summary View
Nov 10, 2015
Summary ToggleZafgen Announces Third Quarter 2015 Financial Results
Company to Host Conference Call at 4:30 PM Eastern Time to Review Progress with Beloranib Program Ends Quarter with Cash, Cash Equivalents and Marketable Securities of $204 Million; Increases Year-End Cash Guidance to Greater than $180 Million BOSTON, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc.
Summary ToggleZafgen Announces Third Quarter 2015 Financial Results
Nov 3, 2015
Summary ToggleZafgen to Host Conference Call to Discuss Third Quarter 2015 Financial Results
BOSTON, Nov. 03, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced that it will host a conference call on Tuesday, November
Summary ToggleZafgen to Host Conference Call to Discuss Third Quarter 2015 Financial Results
Oct 22, 2015
Summary ToggleZafgen Announces Beloranib Program Update Summary ToggleZafgen Announces Beloranib Program Update
Oct 16, 2015
Summary ToggleZafgen Announces Partial Clinical Hold Affecting Beloranib Trials

Investor Conference Call Today, October 16th, at 8:30 a.m. E.T.

Summary ToggleZafgen Announces Partial Clinical Hold Affecting Beloranib Trials
Oct 14, 2015
Summary ToggleZafgen Issues Statement
BOSTON, Oct. 14, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today issued the following statement: "Zafgen recently learned of a
Summary ToggleZafgen Issues Statement
Sep 30, 2015
Summary ToggleZafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Craniopharyngioma Summary ToggleZafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Craniopharyngioma
Sep 28, 2015
Summary ToggleZafgen Announces Transition of Board of Directors

Adds Significant Industry Leadership Experience

Summary ToggleZafgen Announces Transition of Board of Directors
Sep 24, 2015
Summary ToggleZafgen to Present at the Leerink Rare Disease Roundtable Summary ToggleZafgen to Present at the Leerink Rare Disease Roundtable
Sep 10, 2015
Summary ToggleZafgen to Present at Morgan Stanley Global Healthcare Conference Summary ToggleZafgen to Present at Morgan Stanley Global Healthcare Conference
Sep 9, 2015
Summary ToggleZafgen Completes Enrollment of Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes

On Track to Report Interim Results in Late 2015 or Very Early 1Q16

Summary ToggleZafgen Completes Enrollment of Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes